La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Grand Pharmaceutical Group Croissance future

Future contrôle des critères 1/6

Grand Pharmaceutical Group devrait augmenter ses bénéfices et son chiffre d'affaires de 7.1% et de 5.5% par an respectivement. Le BPA devrait croître de de 6.5% par an. Le rendement des capitaux propres devrait être 14.1% dans 3 ans.

Informations clés

2.3%

Taux de croissance des bénéfices

1.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	9.2%
Taux de croissance des recettes	5.6%
Rendement futur des capitaux propres	13.0%
Couverture par les analystes	Low
Dernière mise à jour	23 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

Prévisions de croissance des bénéfices et des revenus

SEHK:512 - Estimations futures des analystes et données financières antérieures (HKD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	13,392	2,526	2,135	2,561	2
12/31/2025	12,419	2,212	1,724	2,090	2
12/31/2024	11,387	2,039	1,635	2,178	2
6/30/2024	10,587	2,409	1,451	1,903	N/A
3/31/2024	10,558	2,144	1,694	2,164	N/A
12/31/2023	10,530	1,880	1,937	2,425	N/A
9/30/2023	10,434	2,139	1,349	2,114	N/A
6/30/2023	10,339	2,398	761	1,804	N/A
3/31/2023	9,951	2,239	773	1,823	N/A
12/31/2022	9,562	2,079	785	1,843	N/A
9/30/2022	9,403	1,995	1,068	1,829	N/A
6/30/2022	9,244	1,910	1,350	1,815	N/A
3/31/2022	8,921	2,156	1,410	1,911	N/A
12/31/2021	8,598	2,403	1,469	2,006	N/A
9/30/2021	8,131	2,340	1,487	2,001	N/A
6/30/2021	7,664	2,277	1,504	1,995	N/A
3/31/2021	7,008	2,035	1,351	1,726	N/A
12/31/2020	6,353	1,793	1,197	1,456	N/A
9/30/2020	6,306	1,558	1,020	1,400	N/A
6/30/2020	6,259	1,323	843	1,345	N/A
3/31/2020	6,425	1,237	790	1,324	N/A
12/31/2019	6,591	1,151	737	1,304	N/A
9/30/2019	6,450	1,048	1,177	1,661	N/A
6/30/2019	6,309	944	1,618	2,017	N/A
3/31/2019	6,134	828	1,326	1,713	N/A
12/31/2018	5,958	713	1,034	1,408	N/A
9/30/2018	5,845	642	535	898	N/A
6/30/2018	5,732	570	36	387	N/A
3/31/2018	5,251	516	N/A	553	N/A
12/31/2017	4,771	461	N/A	720	N/A
9/30/2017	4,480	413	N/A	708	N/A
6/30/2017	4,190	364	N/A	696	N/A
3/31/2017	3,943	317	N/A	736	N/A
12/31/2016	3,696	269	N/A	775	N/A
9/30/2016	3,573	241	N/A	807	N/A
6/30/2016	3,450	213	N/A	839	N/A
3/31/2016	3,348	197	N/A	668	N/A
12/31/2015	3,246	181	N/A	496	N/A
9/30/2015	3,158	187	N/A	439	N/A
6/30/2015	3,071	194	N/A	382	N/A
3/31/2015	3,097	185	N/A	430	N/A
12/31/2014	3,122	175	N/A	477	N/A
9/30/2014	3,040	150	N/A	602	N/A
6/30/2014	2,958	126	N/A	728	N/A
3/31/2014	2,808	113	N/A	760	N/A
12/31/2013	2,658	100	N/A	792	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 512 ( 7.1% par an) est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Les bénéfices de 512 ( 7.1% par an) devraient croître plus lentement que le marché Hong Kong ( 11% par an).

Croissance élevée des bénéfices: Les bénéfices de 512 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 512 ( 5.5% par an) devrait croître plus lentement que le marché de Hong Kong ( 7.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 512 ( 5.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 512 devrait être faible dans 3 ans ( 14.1 %).

Grand Pharmaceutical Group Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Recent updates

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020)

Less than half of directors are independent

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat